Latest Headlines

Latest Headlines

Avista buys another pharma contracting biz

Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.

Valeant gets manufacturing in Middle East with deal for Amoun

With its $800 million deal for Amoun Pharmaceutical, Valeant picks up what the Egyptian drugmaker says is one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East.

AMRI bets $174M on manufacturing with latest buyout

Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.

Charles River spends $212M to beef up its microbial testing

Preclinical CRO Charles River Laboratories is paying $212 million in cash to buy a company focused on quality-control testing, expanding its presence in the market for bacterial detection services.

BioClinica buys a patient recruitment firm to bolster study startup

CRO BioClinica inked a deal to acquire MediciGroup, a patient recruitment and retention outfit that uses technology to keep subjects engaged in trials and minimize dropouts.

Patterson offloads medical unit to private equity firm for $715M, boosts focus on animal health

Just two months after hiring Bank of America to explore a selloff of its medical-equipment unit, distributor Patterson Companies has found a buyer. The Minnesota company announced on Wednesday that it will be selling Patterson Medical to private equity firm Madison Dearborn Partners for $715 million. The deal is expected to close next quarter.

India's Marksans Pharma buys U.S.-based Time-Cap, a trend in the making?

More than a few analysts and company executives are watching Indian drug companies in expectations of consolidation among smaller players and possibly daring moves by mid-cap and larger at home and abroad.

Some Indian drugmakers see M&A preferable to investing in plant upgrades

Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.

UPDATED: Investors erase Zoetis gains as questions emerge about Valeant's pursuit

Just one day after the Wall Street Journal reported that Valeant had made a buyout bid for Zoetis, sending shares of the animal health giant up 11% to an all-time high of $55.48, investors started doubting the deal would happen. As of Monday's stock market opening, no details about the acquisition attempt had been released, and shares opened trading at just over $48--erasing all the gains that had come from the rumor.

Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit

Patterson Companies, a Minnesota-based production and animal health distribution company, completed its $1.1 billion acquisition of Animal Health International in a deal that doubles the size of the company's veterinary unit.